Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

NCT03267940 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

85

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Cholangiocarcinoma Non-resectable
Cholangiocarcinoma, Intrahepatic
Cholangiocarcinoma, Extrahepatic
Gallbladder Adenocarcinoma

Interventions

DRUG: PEGPH20
DRUG: CIS
DRUG: GEM
DRUG: Atezolizumab

Sponsor

Halozyme Therapeutics